GlycoMimetics Inc (GLYC)
0.2964
+0.02
(+5.44%)
USD |
NASDAQ |
May 17, 16:00
0.2964
0.00 (0.00%)
After-Hours: 20:00
GlycoMimetics SG&A Expense (Quarterly): 5.09M for March 31, 2024
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 5.09M |
December 31, 2023 | 4.312M |
September 30, 2023 | 4.522M |
June 30, 2023 | 4.857M |
March 31, 2023 | 5.522M |
December 31, 2022 | 4.731M |
September 30, 2022 | 3.845M |
June 30, 2022 | 5.455M |
March 31, 2022 | 5.056M |
December 31, 2021 | 4.548M |
September 30, 2021 | 4.142M |
June 30, 2021 | 4.237M |
March 31, 2021 | 4.188M |
December 31, 2020 | 4.011M |
September 30, 2020 | 4.058M |
June 30, 2020 | 4.235M |
March 31, 2020 | 4.44M |
December 31, 2019 | 3.868M |
September 30, 2019 | 3.381M |
June 30, 2019 | 3.751M |
March 31, 2019 | 3.36M |
December 31, 2018 | 2.921M |
September 30, 2018 | 2.79M |
June 30, 2018 | 2.847M |
Date | Value |
---|---|
March 31, 2018 | 2.855M |
December 31, 2017 | 2.816M |
September 30, 2017 | 2.402M |
June 30, 2017 | 0.0025M |
March 31, 2017 | 2.092M |
December 31, 2016 | 2.298M |
September 30, 2016 | 1.984M |
June 30, 2016 | 2.312M |
March 31, 2016 | 2.056M |
December 31, 2015 | 1.961M |
September 30, 2015 | 2.133M |
June 30, 2015 | 1.806M |
March 31, 2015 | 1.905M |
December 31, 2014 | 2.117M |
September 30, 2014 | 1.648M |
June 30, 2014 | 1.605M |
March 31, 2014 | 1.225M |
December 31, 2013 | 0.824M |
September 30, 2013 | 0.80M |
June 30, 2013 | 0.668M |
March 31, 2013 | 0.606M |
December 31, 2012 | 0.5436M |
September 30, 2012 | 0.5509M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
3.381M
Minimum
Sep 2019
5.522M
Maximum
Mar 2023
4.412M
Average
4.274M
Median
SG&A Expense (Quarterly) Benchmarks
Altimmune Inc | 5.312M |
Lyell Immunopharma Inc | 13.49M |
Amicus Therapeutics Inc | 88.03M |
InfuSystems Holdings Inc | 17.07M |
Nanoviricides Inc | 0.6109M |